File downloaded on 2026-10-31
Source URL: https://medicines.health.europa.eu/veterinary/en/600001882882

Nobivac NXT HCPChFeLV (--) + (--) + (--) + (--) - Lyophilisate and solvent for suspension for injection

Authorised

- Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient
- Chlamydia felis, strain Baker, Live
- Feline panleucopenia virus, strain MW-1, Live
- Feline calicivirus, strain F9, Live
- Felid herpesvirus 1, strain G2620A, Live

Product identification

Medicine name:
Nobivac NXT HCPChFeLV (--) + (--) + (--) + (--) + (--) - Lyophilisate and solvent for suspension for injection

Active substance:
Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Chlamydia felis, strain Baker, Live

Feline panleucopenia virus, strain MW-1, Live

Feline calicivirus, strain F9, Live

Felid herpesvirus 1, strain G2620A, Live

Target species:
Cat

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Presentation_strength:$10^{6.6}$ – $10^{9.3}$ RP Index:4
Chlamydia felis, strain Baker, Live

Presentation_strength:$10^{4.1}$ – $10^{7.0}$ $TCID_{50}$ Index:3
Feline panleucopenia virus, strain MW-1, Live

Presentation_strength:$10^{5.2}$ – $10^{6.4}$ $TCID_{50}$ Index:2
Feline calicivirus, strain F9, Live

Presentation_strength:$10^{4.6}$ – $10^{7.0}$ PFU Index:1
Felid herpesvirus 1, strain G2620A, Live

Presentation_strength:$10^{5.8}$ – $10^{7.1}$ PFU Index:0

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI06AX

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Vial (glass), Package_size:Lyophilisate: 25 vials + solvent: 25 vials, Content:Lyophilisate: 1 dose + solvent: 0.5 ml
Packaging:Vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 1 dose + solvent: 0.5 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
29/07/2026

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
29/07/2026

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 25/08/2026
Download

ema-puar-v6520-nobivacnxthcpchfelv-initial-en.pdf